Purpose:
Breast cancer is the most frequent cancer among women and the most important cause of death. Surgery and chemotherapy are the common treatment of the breast cancer, but increasing drug resistance has created many
challenges in its treatment. The present study aimed to investigate the anti-cancer function of free and nano-encapsulated
hydroxytyrosol on the MCF-7 breast cancer cell line.
Methods:
The poly lactide-co-glycolide-co-polyacrylic acid (PLGA-co-PAA) nano-encapsulated Hydroxytyrosol was synthesized, and the MTT assay was performed to evaluate the anti-proliferative and anti-tumor effects of both free and nanoencapsulated Hydroxytyrosol. After the extraction of RNA from the treated and control cancer cells, cDNA synthesis was
performed and the expression of P21, P27, and Cyclin D1 genes were evaluated by Real-Time PCR.
Results:
The results of the study showed that free (12 ppm and 72 hours) and nano-encapsulate (10 ppm and 24 hours) hydroxytyrosol resulted in 50% death (IC50) of the cancer cells and increased by increasing the concentration and time. Also,
free and nano-encapsulated hydroxytyrosol increased the expression of P21 and P27 genes and reduced the expression of
Cyclin D1 in breast cancer cells. In general, the nano-encapsulated hydroxytyrosol showed more anticancer function than
the free hydroxytyrosol.
Conclusion:
The present study illustrated that the hydroxytyrosol could lead to the cell death in MCF-7 breast cancer by
regulating the cell cycle. Also, the nano-encapsulation of Hydroxytyrosol enhanced the Hydroxytyrosol anticancer function
by PLGA-co-PAA. However, for more accurate results, further studies on animal models are necessary.
Synthesis, Characterization and Anti-Cancer Therapeutic Potential of Withanolide-A with 20nm sAuNPs Conjugates Against SKBR3 Breast Cancer Cell Line
